CD274 and colorectal carcinoma: For the majority of metastatic CRC patients with microsatellite‐stable (MSS) or mismatch repair‐proficient (pMMR) phenotypes, the objective response rate (ORR) to single‐agent PD‐1/PD‐L1 inhibitor therapy is exceedingly low, yielding minimal clinically beneficial effects [37, 42, 43].